Related Experiment Videos
Clinical update: novel targets in multiple myeloma
1Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Seminars in Oncology
|April 1, 2005
Summary
Novel therapies targeting multiple myeloma (MM) cells and their bone marrow environment show promise. Bortezomib and Revimid offer new hope for patients with relapsed refractory MM.
Area of Science:
- Hematology
- Oncology
- Pharmacology
Background:
- Multiple myeloma (MM) is a cancer of plasma cells.
- Resistance to conventional therapies remains a challenge in MM treatment.
- Understanding the bone marrow microenvironment's role is crucial.
Purpose of the Study:
- To review novel therapeutic strategies for multiple myeloma.
- To highlight agents targeting MM cells and their interactions.
- To discuss the clinical potential of new MM treatments.
Main Methods:
- Review of preclinical models and clinical trial data.
- Focus on targeted therapies including proteasome inhibitors and immunomodulatory drugs.
- Evaluation of drug efficacy in relapsed refractory MM.
Main Results:
- Novel therapies demonstrate efficacy in preclinical and clinical settings.
- Bortezomib and Revimid have rapidly advanced to clinical use.
- These agents show responses in patients with relapsed refractory MM.
Conclusions:
- Targeting MM cells and the bone marrow milieu overcomes resistance.
- Bortezomib and Revimid offer significant promise for improving MM patient outcomes.
- Further clinical evaluation is underway for earlier disease treatment.